empoweringmuscleempoweringlives
We are developing potential medicines that improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
cardiovascular disease
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
NEUROMUSCULAR DISEASE
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
Press Releases
- Cytokinetics Reports First Quarter 2019 Financial Results
- Cytokinetics to Hold Annual Meeting of Stockholders
- Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
Annual Report
Pipeline
We have robust pipeline of small molecule muscle activators and inhibitors, including omecamtiv mecarbil, reldesemtiv, CK-274, AMG 594 and CK-601.
Careers
We seek exceptional individuals to join us in our mission to develop the next generation of novel small molecule muscle-directed potential medicines.